Skip to content

Comparing How Well Children Accept IV Needles After Using Intranasal Dexmedetomidine Versus Sublingual Midazolam

Comparison of Acceptance of Intravenous Cannulation in Children following Premedication with Intranasal Dexmedetomidine versus Sublingual Midazolam- A Randomized Controlled Trial - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084259
Enrollment
100
Registered
2025-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Intranasal dexmedetomidine group: The patient will receive intranasal dexmedetomidine (2 g/kg body weight), once at the time of 60 minutes prior to induction Control Intervention1: Subl

Sponsors

Sir Gangaram Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: American Society of Anaesthesiologists (ASA) Grade I & II Age group 2-6 years Body weight less than 20 kgs

Exclusion criteria

Exclusion criteria: Known allergy/ hypersensitivity to dexmedetomidine or midazolam Parents refusal History of obstructive sleep apnea Non visible/ non palpable veins Nasal/ tonsillar abnormalities or blockage

Design outcomes

Primary

MeasureTime frame
Acceptance of IV cannulationTimepoint: During the preoperative period after 60 mins of giving dexmedetomidine in group 1 and 30 mins after midazolam in group 2

Secondary

MeasureTime frame
Ramsay sedation scores, Parental Separation Anxiety score, Haemodynamic parametresTimepoint: 60 mins prior to induction to 60 mins after extubation for group 1 & 30 mins prior to induction to 60 mins after extubation for group 2

Countries

India

Contacts

Public ContactPrachi Jha

Sir Gangaram Hospital New Delhi

prachijha1995@gmail.com8877033922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026